Trade Name(s)

  • Sivextro

Ther. Class.

Pharm. Class.


Treatment of acute bacterial skin and skin structure infections (ABSSSI).


Inhibits bacterial protein synthesis at the level of the 23S ribosome of the 50S subunit.

Therapeutic Effect(s):

Bacteriostatic action against enterococci, staphylococci and streptococci, resulting is resolution of infection.


Active against Staphylococcus aureus including methicillin-resistant strains (MRSA), Streptococcus pyogens, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, Streptococcus constellatus) and Enterococcus faecalis.


Absorption: IV administration results in complete bioavailability; well absorbed (91%) following oral administration, rapidly converted by phosphatases to its active form.

Distribution: Penetrates interstitial fluid space of adipose and skeletal muscle resulting in similar levels to plasma.

Metabolism and Excretion: Eliminated via liver with inactive metabolites excreted in feces (82%) and urine (18%); <3% excreted unchanged in urine or feces.

Half-life: 12 hr.

TIME/ACTION PROFILE (blood levels)

POunknown2.5 hr24 hr
IVrapidend of infusion24 hr


Contraindicated in:

  • Uncontrolled HTN, pheochromocytoma, thyrotoxicosis, or concurrent use of sympathomimetic agents, vasopressors, or dopaminergic agents (↑ risk of hypertensive response);
  • Concurrent or recent (<2 wk) use of monoamine oxidase (MAO) inhibitors (↑ risk of hypertensive response);
  • Carcinoid syndrome or concurrent use of SSRIs, TCAs, triptans, meperidine, or buspirone (↑ risk of serotonin syndrome).

Use Cautiously in:

  • Neutropenia (safety and efficacy not established if WBC <1000 cells/mm3 )
  • OB:  Use in pregnancy only if potential maternal benefit justifies potential fetal risk;
  • Lactation: Use cautiously if breast feeding;
  • Pedi:  Safety and effectiveness not established.

Adverse Reactions/Side Effects

CNS: dizziness, headache


Misc: infusion reactions

* CAPITALS indicate life-threatening.
Underline indicate most frequent.




PO IV (Adults): 200 mg once daily for 6 days.


Lyophilized powder for injection (requires reconstitution and dilution): 200 mg/vial

Tablets: 200 mg


  • Assess for infection (vital signs; appearance of wound, sputum, urine, and stool; WBC) at beginning of and during therapy.
  • Obtain specimens for culture and sensitivity prior to initiating therapy. First dose may be given before receiving.
  • Monitor bowel function. Diarrhea, abdominal cramping, fever, and bloody stools should be reported to health care professional promptly as a sign of Clostridium difficile-associated diarrhea (CDAD). May begin up to several mo following cessation of therapy.

Lab Test Considerations:

Consider alternate therapies in patients with neutrophil counts <1000 cells/mm3 .

  • May cause anemia.

Potential Diagnoses


  • Dose adjustment is not necessary when switching from IV to oral dose.
  • PO May be administered with or without food.

IV Administration

  • Intermittent Infusion:  Reconstitute each vial with 4 mL of sterile water for injection. Gently swirl and let vial stand until completely dissolved; avoid shaking. Diluent:   Dilute further with 250 mL of 0.9% NaCl by slowing injecting reconstituted solution into 250 mL bag. Gently invert bag to mix; avoid shaking to minimize foaming. Solution is clear and colorless to pale yellow; do not administer solutions that are discolored or contain particulate material. Must be used within 24 hrs of reconstitution at room temperature or under refrigeration.
  • Rate: Infuse over 1 hr.
  • Y-Site Incompatibility
    • solutions containing calcium or magnesium
    • Lactated Ringer's
    • Hartmann's solution

Patient/Family Teaching

  • Advise patients taking oral tedizolid to take as directed, for full course of therapy, even if feeling better. Take missed doses as soon as remembered up to 8 hrs before next dose; if less than 8 hrs before next dose, wait until next scheduled dose. Do not double dose.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Instruct patient to notify health care professional if changes in vision occur or immediately if diarrhea, abdominal cramping, fever, or bloody stools occur and not to treat with antidiarrheals without consulting health care professionals.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected, or if breast feeding.
  • Advise patient to notify health care professional if no improvement is seen in a few days.

Evaluation/Desired Outcomes

Resolution of signs and symptoms of infection. Length of time for complete resolution depends on organism and site of infection.

tedizolid is a sample topic from the Davis's Drug Guide.

To view other topics, please or .

Emergency Central is a collection of disease, drug, and test information including 5-Minute Emergency Medicine Consult, Davis’s Drug, McGraw-Hill Medical’s Diagnosaurus®, Pocket Guide to Diagnostic Tests, and MEDLINE Journals created for emergency medicine professionals. .